• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Altius Minerals Corp
American Express
Biolargo Inc
Citius Pharmaceuticals, Inc. - Common Stock
Fabled Silver Gold Corp
MDB Capital Holdings, LLC - Class A common
Mayfair Gold Corp
Mitsubishi Estate Co. Ltd
Seven Arts Entertainment Inc
State Street SPDR S&P Semiconductor ETF
Super League Enterprise, Inc. - Common Stock
Tandy Leather Fctry
Teledyne Technologies Incorporated Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

67.74 +0.19 (+0.28%)
Delayed Quote Updated: 4:00 PM EDT, Oct 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,035,896
Open 68.04
Bid (Size) 67.74 (2,600)
Ask (Size) 67.76 (100)
Prev. Close 67.55
Today's Range 67.55 - 68.79
52wk Range 52.75 - 93.42
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 16, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
October 11, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Performance

52-Week Range 27.5% below 52-week high
67.74
52.7552W Low 93.4252W High
1 Week 1.8% below 1-week high
62.861W Low 69.001W High

BridgeBio Pharma, Inc. - Common Stock (BBIO) traded between $52.75 and $93.42 over the past 52 weeks and last traded at $67.74, 27.5% below its 52-week high. Over the past week it ranged between $62.86 and $69.00.

Past 12 Months
+4.3%
+1.7%
-17.8%
-11.1%
-13.4%
+20.4%
1W +$2.80
1M +$1.16
3M -$14.71
6M -$8.44
YTD -$10.50
1Y +$11.48

BBIO was +20.4% over the past year, -11.1% over six months, -13.4% year to date, +4.3% in the last week.

12 Months vs Market
BBIO
+20.4%
DIA
+13.0%
SPY
+15.2%
QQQ
+18.6%
IWM
+11.4%

Over the past 12 months BBIO returned +20.4% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.2%, QQQ (Nasdaq 100) +18.6% and IWM (Russell 2000) +11.4%.

Volume & Liquidity 1.26× 3-mo avg
Today 3,035,896 3-mo avg 2.4M
1W
2.5M
1M
2.8M
3M
2.4M
6M
3.0M
YTD
2.9M
1Y
2.8M

BBIO most recently traded 3,035,896 shares against a 3-month average daily volume of 2.4M.

More News

Read More
News headline image
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
October 11, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
October 06, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup ↗
August 11, 2026
Via Chartmill
News headline image
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
October 06, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
October 06, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
October 05, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
October 05, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status ↗
September 26, 2026
Via MarketBeat
News headline image
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
September 23, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 18, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
September 09, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
September 02, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Participate in September Investor Conferences
September 01, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
August 31, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
August 30, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
August 26, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
August 24, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio (BBIO) Q2 2026 Earnings Call Transcript ↗
August 19, 2026
Via The Motley Fool
Topics Earnings
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
August 16, 2026
Via The Motley Fool
News headline image
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. ↗
August 14, 2026
Via The Motley Fool
News headline image
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
August 14, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
August 13, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 11, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
What is the current price of BridgeBio Pharma, Inc. - Common Stock?
The current price of BridgeBio Pharma, Inc. - Common Stock is 67.74
When was BridgeBio Pharma, Inc. - Common Stock last traded?
The last trade of BridgeBio Pharma, Inc. - Common Stock was at 10/21/26 04:00 PM ET
What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 10.87B
How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
BridgeBio Pharma, Inc. - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap